CenTrial Logo

Managing Impulse Control Disorders in Parkinson's Disease


Clinical trial shows clonidine has potential to help Parkinson's patients with impulse control disorders

In Parkinson's disease, individuals often encounter impulse control disorders (ICDs) like compulsive behaviors or addiction-related tendencies. These issues significantly impact daily life. To tackle these challenges, researchers conducted a comprehensive clinical trial across multiple medical centers to investigate whether clonidine, a medication targeting specific receptors in the body, could effectively alleviate these impulse control disorders in Parkinson's patients.

Clinical trial

The trial involved 41 individuals diagnosed with Parkinson's disease and experiencing impulse control disorders. These participants were enrolled in an 8-week trial that was both randomized and double-blinded, meaning neither the patients nor the researchers knew who received clonidine or the placebo. The primary aim was to evaluate any changes in symptom severity using a specialized assessment tool called the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale (QUIP-RS).


Between May 2019 and September 2021, the trial took place across multiple centers, with some patients receiving 75 μg of clonidine twice a day while others received a placebo. At the end of the 8 weeks, the researchers analyzed the data to understand the impact of clonidine on the severity of impulse control disorders in Parkinson's disease.



The trial's results showed interesting trends. While the difference in success rates between the clonidine and placebo groups in reducing QUIP-RS scores at 8 weeks wasn't statistically significant, noteworthy patterns emerged. Approximately 42.1% of individuals receiving clonidine experienced improvement compared to 35.0% in the placebo group. This suggested a potential benefit associated with clonidine usage.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Moreover, those taking clonidine exhibited a more significant reduction in their total QUIP-RS score (reduced by 11.0 points) compared to the placebo group (reduced by 3.6 points) at the end of the 8-week period. This indicated a positive impact of clonidine on the severity of impulse control disorders in Parkinson's patients.


The trial also noted that participants tolerated clonidine well, implying its safety and potential suitability as a treatment option for managing impulse control disorders in Parkinson's disease. However, due to the trial's sample size, researchers couldn't definitively conclude clonidine's superiority over the placebo. Consequently, they suggest the necessity for a larger-scale phase 3 trial to confirm these findings.



While this trial didn't conclusively establish clonidine's clear advantage over the placebo in reducing impulse control disorders in Parkinson's disease, it did reveal encouraging trends. The greater reduction in QUIP-RS scores among those taking clonidine indicates its potential effectiveness in managing these challenging symptoms.


This research represents a significant step forward in understanding and addressing impulse control disorders in Parkinson's disease. Future studies with larger participant groups will be crucial in confirming these initial findings and determining the potential role of clonidine as a treatment option for managing impulse control disorders in Parkinson's disease.


Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Whether you're healthy or have a medical condition you can participate in a clinical trial.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.